TACR1 and neoplasm: It has been shown that NK-1R antagonists are very effective against tumor cells expressing a higher level of the truncated isoform of the NK-1R [59], and it is known that normal cells express a lower number of the truncated form than cancer cells and that, in the latter cells, the expression of the truncated form is higher than that of the full-length [18,82].